June 21, 2021
Curing Cancer with a Little Blue Pill?!
Dr. David Bruyette, Anivive's CMO, talks about his company, a pharmaceutical startup looking for medical solutions for unmet needs in the veterinary space, that has created LAVERDIA™-CA1 (verdinexor), the first pill to treat cancer, in this case lymphoma in dogs, which may someday benefit humans, too.
NPR's Dog Talk ® (and Kitties Too!)
June 6, 2021
Can a dog vaccine for Valley fever lead to a human one?
Anivive's work on an antifungal vaccine to prevent canine Valley Fever is referenced in this Freethink article.
June 1, 2021
Deadly Fungi Are the Newest Emerging Microbe Threat All Over the World
Anivive's work with Dr. John Galgiani and his research team at the Valley Fever Center for Excellence at the University of Arizona College of Medicine is gaining attention as the threat of systemic fungal diseases escalates globally.
April 12, 2021
Anivive sprints to market with pet chemotherapy
Anivive Lifesciences Inc. is taking its first pet-specific drug to market after 3.5 years and $5 million in research and development costs.
Orange County Business Journal
January 18, 2021
FDA endorses canine epilepsy and lymphoma drugs
Medications from Pegasus Laboratories and Anivive Lifesciences earned conditional approvals.
Today’s Veterinary BusinessRead More
August 31, 2020
Cats point the way to potential COVID-19 remedies
Anivive Lifesciences, is working on a COVID-19 antiviral drug that’s inspired by cats, and it has new preclinical research findings to back up the project.
June 9, 2019
A drugs life: How David Bruyette’s biotech startup is changing the way veterinary products come to market
Anivive Lifesciences starts with unmet therapeutic needs and employs high-tech research methods to identify compounds that could meet those needs.